Drug Profile

Loncastuximab tesirine - ADC Therapeutics

Alternative Names: ADCT-402; Anti-CD19-PBD-conjugate-ADC; Lonca; Lonca-T; loncastuximab tesirine-lpyl; MT-2111; ZYNLONTA

Latest Information Update: 21 Jan 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ADC Therapeutics; Spirogen
Developer ADC Therapeutics; Swedish Orphan Biovitrum; Tanabe Pharma Corporation
Class Antineoplastics; Benzodiazepines; Drug conjugates; Immunotoxins; Monoclonal antibodies; Pyrroles
Mechanism of Action Alkylating agents; DNA cross linking agents

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Mantle-cell lymphoma; Diffuse large B cell lymphoma
New Molecular Entity Yes

Marketed Diffuse large B cell lymphoma
Preregistration B-cell lymphoma
Phase II Follicular lymphoma; Marginal zone B-cell lymphoma; Waldenstrom's macroglobulinaemia
Phase I/II Mantle-cell lymphoma
Phase I Non-Hodgkin's lymphoma
Discontinued Precursor B-cell lymphoblastic leukaemia-lymphoma

08 Jan 2026 ADC Therapeutics announces intention to submit supplemental BLA to US FDA for Diffuse large B-cell lymphoma (Combination therapy, Second-line therapy or greater) in the first half of 2027
08 Jan 2026 ADC Therapeutics anticipates potential approval of loncastuximab tesirine for Diffuse large B-cell lymphoma (Combination therapy, Second-line therapy or greater) in the US in mid 2027
06 Dec 2025 Updated efficacy and adverse events data from a phase II trial in Waldenstrom's macroglobulinaemia presented at the 67th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2025)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com